2022-09-27 Meeting notes

Slides

Chat History

From Hung Luu to Everyone 12:06 PM

CLSI Auto-17 Semantic Interoperability, the white paper on LIVD should be published soon.

From Andrea Pitkus to Everyone 12:06 PM

Excellent, Dr. Luu

From Pam Banning to Everyone 12:08 PM

apologies for being late 9:08 Pacific. Hope the roster can be updated

From MM to Everyone 12:09 PM

can I get a copy of the community plan?

Me to MM (Direct Message) 12:09 PM

if you tell me who you are - and your email

From MM to Me (Direct Message) 12:10 PM

This is Mehdi Maghsoodnia

Me to MM (Direct Message) 12:11 PM

ok

From Carolyn Hiller to Everyone 12:15 PM

Can you provide more examples of patient groups?

From Andrea Pitkus to Everyone 12:21 PM

Regarding patient advocates, ASCP has Patient Champions, and one I know is also on the PT Advocate Board for the Natl Kidney Foundation and an academic medical ctr. They would be in tune to patient impacts of lab testing

From SZARFMAN to Everyone 12:22 PM

From Qin Ryan:

IO testing companion device/kit and indicated products.

Since last decade, immunotherapy (IO) has become the main steam of precision medicine in oncology practice for cancer treatments. Presently, there are 6 approved IO products in US. Each one of them has its own testing kit to evaluate targeted molecule expression for a specific indication.

The threshold of target positivity IO treatment selection are determined by the level of biomarker expression.  The expression level cut of varies depending on the test specification, methodology, clinical trial experience on tumor tissue testing and the CD brand specified for each IO.  The table below summarized tissue base CDs. The liquid biopsy sample based tests are not included.

Recording